Delafloxacin

德拉沙星

Report date: 2026/05/26 20:00:28
NMEQIDP

Base Information

Drug NameDelafloxacin
Drug Alias NameDelafloxacin Meglumine德拉沙星葡甲胺BaxdelaQuofenixWQ-3034 +[9] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Quinolone antibiotics
Mechanisms of ActionBacterial DNA gyrase inhibitorsTopoisomerase IV inhibitors
TargetsTopoisomerase IVBacterial DNA gyrase
Therapy Area/IndicationsCommunity Acquired PneumoniaCommunity-acquired bacterial pneumoniaAcute bacterial skin and skin structure infections +[10] 
Global Approved IndicationsAcute bacterial skin and skin structure infectionsSkin Diseases, Bacterial
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesUkraine +[33] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesWakunaga Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMelinta TherapeuticsXediton Pharmaceuticals IncMelinta Therapeutics Inc +[4] 
Inactive CompaniesMenarini GroupJiangsu Aosaikang Pharmaceutical Co Ltd
Active IndicationsCommunity Acquired PneumoniaCommunity-acquired bacterial pneumoniaAcute bacterial skin and skin structure infections +[4] 
Inactive IndicationsHepatic InsufficiencySurgical Wound InfectionPneumonia +[6] 

Other Information

ATC CodeJ01MA23
Related LinksWikipediaDrugBankKEGG